Business Context and Reporting Period
This Form 8-K was filed by Ekso Bionics Holdings, Inc. (the "Company") on December 30, 2016. The filing reports the entry into a material definitive agreement and the creation of a direct financial obligation. The Company is a Nevada corporation with principal executive offices in Richmond, California.
Key Financial Metrics and Obligations
- Debt Facility: Entered into a Loan and Security Agreement with Western Alliance Bank for up to $10 million in total term loans.
- Tranche Structure:
- Term A Loan: $7 million (disbursed on the Closing Date).
- Term B Loan: $3 million (conditional on the Company raising at least $15 million in net equity proceeds by December 31, 2017).
- Interest Rate: Floating rate equal to 30-day U.S. LIBOR plus 5.41% per annum.
- Amortization and Maturity:
- Interest-only payments until January 1, 2018 (or July 1, 2018 if Term B is funded).
- Principal amortizes ratably over 36 months (or 30 months if Term B is funded).
- Final maturity date: January 1, 2021.
- Fees:
- Non-refundable loan fee: $35,000 (paid at closing) plus $15,000 if Term B is advanced.
- Prepayment fee: 1.0% of principal if prepaid within the first anniversary.
- Exit fee: 3.50% of each Term Loan payable upon acceleration, voluntary prepayment, or maturity.
- Success Fee: $250,000 payable upon a change of control, asset sale, or if the stock price reaches $8.00 for five successive business days. Payable in cash or stock.
- Liquidity Covenant: Must maintain unrestricted cash equal to at least three months of "Monthly Cash Burn."
Material Changes
The primary material change is the establishment of a new $7 million debt facility (with potential for an additional $3 million) to fund working capital and general business requirements. This represents a significant increase in the Company's indebtedness and the creation of a first-priority security interest in substantially all assets of the Borrower and its domestic subsidiaries, excluding the intellectual property itself. The Company is also required to pledge 100% of domestic subsidiary stock and 65% of foreign subsidiary stock.
Guidance, Risks, and Covenants
- Use of Proceeds: Restricted to working capital and general business requirements.
- Covenants: The agreement includes customary negative covenants restricting asset dispositions, mergers, additional indebtedness, liens, dividends, capital expenditures over $150,000, and changes of control.
- Events of Default: Include non-payment, covenant violations, material adverse effects, bankruptcy, and judgments exceeding $250,000.
- Management Commentary: The filing references a press release issued on January 6, 2017, but does not contain specific forward-looking financial guidance or revenue projections within the text of this 8-K.
Investor Verification Checklist
- Verify the Company's current cash balance to ensure compliance with the "three months of Monthly Cash Burn" liquidity covenant.
- Confirm whether the Company has raised the required $15 million in net equity proceeds to trigger the $3 million Term B Loan.
- Review the Company's stock price history to assess the likelihood of triggering the $250,000 Success Fee (requires $8.00/share for 5 consecutive days).
- Examine the Company's capital expenditure plans to ensure they do not exceed the $150,000 threshold without lender approval.
- Check for any existing indebtedness that might conflict with the new negative covenants regarding additional liens or indebtedness.